Coagulase-negative staphylococcal dissease: Emerging therapies for the neonatal and pediatric patient

Current Opinion in Infectious Diseases

Volumn 17, Issue 3, 2004, Pages 237-241

  Weisman, Leonard E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

CONS; Infant; Newborn; Pediatric; Prevention; Treatment

Indexed keywords

HABEKACIN; LINEZOLID;

ANTIBODY SCREENING; CENTRAL VENOUS CATHETERIZATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; NEWBORN INFECTION; PEDIATRICS; REVIEW; SEPSIS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; COAGULASE; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 2542638532     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200406000-00011     Document Type: Review

References (34)

1. Fanaroff AA, Korones SB, Wright LL, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. Pediatr Infect Dis J 1998; 17:593-598.
2. Gladstone IM, Ehrenkranz RA, Edberg SC, et al. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990; 9:819-825.
3. Gray JE, Richardson DK, McCormick MC, Goldmann DA. Coagulase-negative staphylococcal bacteremia among very low birth weight infants; relation to admission illness severity, resource use and outcome. Pediatrics 1995; 95:225-230.
4. Brodie SB, Sands KE, Gray JE, et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J 2000; 19:56-62.
5. Sohn AH, Garrett DO, Sinkowitz-Cochran RL, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the First National Point-Prevalence Survey. J Pediatr 2001; 139:821-827.
6. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285-291.
7. Fischer GW, Cieslak TJ, Wilson SR, et al. Opsonic antibodies to Staphylococcus epidermidis: In vitro and in vivo studies using human intravenous immune globulin. J Infect Dis 1994; 169:324-329.
8. Fanaroff AA, Korones SB, Wright LL, Wright EC. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med 1994; 330:1107-1113.
9. Weisman LE, Wilson SR, Fischer GW. Intravenous immunoglobulin (IV IGG) lots used in clinical trials to prevent late-onset infection in the high risk neonate contained variable staphylococcus epidermidis antibody activity. Pediatr Res 1996; 39:304A.
10. Weisman LE, Cruess DF, Fischer GW. Opsonic activity of commercially available intravenous immunoglobulin preparations. Pediatr Infect Dis J 1994; 13:1122-1125.
11. Celkan T, Ozkam A, Apak H, et al. Bacteremia in childhood cancer. J Trop Pediatr 2002; 48:373-377.
12. Girmenia C, Lo Coco F, Breccia M, et al. Infectious complications in patients with promyelocytic leukemia treated with AIDA regimen. Leukemia 2003; 17:925-930.
13. Santucci SG, Gobara S, Santos CR, et al. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 2003; 53:6-13.
14. Janssen PA, Selwood BL, Dobson SR, et al. To dye or not to dye: a randomized, clinical trial of a triple dye/alcohol regime versus dry cord care. Pediatrics 2003; 111:15-20.
15. Donnell SC, Taylor N, van Saene HK, et al. Infection rates in surgical neonates and infants receiving parenteral nutrition: a five year prospective study. J Hosp Infect 2002; 52:273-280.
16. Diekema DJ, Pfaller MA, Jones RN, SENTRY Participants Group. Age related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program 1997-2000. Int J Antimicrob Agents 2002; 20:412-418.
17. Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr Infect Dis J 2003; 22:17-21.
18. Issacs D, Australasian Study Group for Neonatal Infections. A ten year, multicentre study of coagulase negative staphylococcal infection in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed 2003; 88:F89-F93.
19. Eggink BH, Rowen JL. Primary osteomyelitis and suppurative arthritis caused by coagulase-negative staphylococci in a preterm neonate. Pediatr Infect Dis J 2003; 22:572-573.
20. Center KJ, Reboli AC, Hubler R, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of Staphylococcus warneri. J Clin Microbiol 2003; 41:4660-4665
21. Huang SY, Tang RB, Chen SJ, Chung RL. Coagulase negative staphylococcal bacteremia in crtically ill children: risk factors and antimicrobial susceptibility. J Microbiol Immunol Infect 2003; 36:51-55.
22. Urrea M, Pons M, Serra M, et al. Prospective incidence study of nosocomial infections in a pediatric intensive care unit. Pediatr Infect Dis J 2003; 22:490-494.
23. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial blood stream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22:686-691.
24. Carothers TS, Coats DK, McCreery KM, et al. Quantification of incidental needle and suture contamination during strabismus surgery. Binocul Vis Starbismus Q 2003; 18:75-79.
25. Lieb DF, Scott IU, Flynn HW Jr, et al. Open globe injuries with positive introcular cultures: factors influencing final visual acuity outcomes. Ophthalmology 2003; 110:1560-1566.
26. Mandy GT, Weisman LE, Horwith G, et al. Safety of a Staphylococcus aureus intravenous human immune globulin in very-low-birth-weight neonates [abstract]. Pediatr Res 2000; 47:343A.
27. Weisman LE, Schuman RF, Lukomska E, et al. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody [abstract]. Pediatr Res 2001; 49:301A.
28. Weisman LE, Fischer GW, Mandy GT, et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody in healthy adults [abstract]. Pediatr Res 2002; 51:270A.
29. Weisman LE, Mandy GT, Garcia-Prats JA, et al. Safety and pharmacokinetics of a human chimeric anti-staphylococcal monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report [abstract]. Pediatr Res 2003; 53:315A.
30. Bloom BT, Kueser TJ, Oelberg DG, et al. A phase I, multicenter study of safety and tolerance of a donor selected staphylococcal immune globulin in very low birth weight infants [abstract]. Pediatr Res 2003; 53:316A.
31. Bloom B, Schelonka R, Kueser T, et al. Multicenter phase II study to assess safety and preliminary efficacy of Veronate®, a donor selected anti-staphylococcal immune globulin in very low birth weight infants. [abstract] Pediatr Res 2004; 55:392A.
32. Suzuki K. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 2003; 45:301-306.
33. Kaplan SL, Deville JG, Yogev R, et al. Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677-686.
34. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant garm-positive infections in neonates. Pediatr Infect Dis J 2003; 22 (9 Suppl):S158-S163.